TITLE

Cost-effectiveness analysis of Mammostrat compared with Oncotype DX to inform the treatment of breast cancer

AUTHOR(S)
Mislick, Kimberly; Schonfeld, Warren; Bodnar, Carolyn; Kuo Bianchini Tong
PUB. DATE
January 2014
SOURCE
ClinicoEconomics & Outcomes Research;2014, Vol. 6, p37
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: To compare the cost-effectiveness of the tumor subtyping assays Mammostrat® and Oncotype DX® for assessing risk of recurrence in early-stage breast cancer and the potential benefit of adjuvant chemotherapy. Methods: Cost-effectiveness analysis from a US third-party payer perspective. A 10 year Markov model was developed to estimate costs and effects of using each method of risk assessment. The percentages of patients assessed as high, moderate, or low risk were obtained from multicenter, prospective, randomized controlled trials. The analysis simulated the experience of women progressing through various model states representing clinical treatments and subsequent disease. Published recurrence data for Mammostrat® were adjusted appropriately to account for differences between definitions and samples of Oncotype DX® and Mammostrat® in the original clinical trials. Cost and utility data were obtained from previously published studies. Sensitivity analyses examined how base-case results might differ when input values and assumptions varied. Results: Base-case costs for women assessed using Mammostrat® were $15,782, compared with $18,051 for women assessed with Oncotype DX®. Thus, cost savings of $2,268 resulted from using Mammostrat®. Both Mammostrat® and Oncotype DX® resulted in similar life years (9.880 and 9.882) and quality-adjusted life years (7.935 and 7.940), respectively. Sensitivity analyses demonstrated that the assumptions made about recurrence are the key drivers of model results. Discussion: Cost savings associated with the use of Mammostrat® instead of Oncotype DX® are largely due to the difference in cost between the two tests. Since survival and quality-adjusted life years were similar using either assay, Mammostrat® has economic advantages for women with early-stage breast cancer.
ACCESSION #
94750515

 

Related Articles

  • Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer. Tsoi, Daphne T.; Inoue, Miho; Kelly, Catherine M.; Verma, Sunil; Pritchard, Kathleen I. // Oncologist;May2010, Vol. 15 Issue 5, p457 

    Purpose. Most guidelines for hormone receptor (HR)-positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost. There has been recent incorporation of gene expression analysis in aiding decision...

  • Comment on: 'Subgroup effects in a randomized trial of different types and doses of exercise during breast cancer chemotherapy'. Beijers, A J M; Verhulst, A L J; Mols, F; Vreugdenhil, G // British Journal of Cancer;5/26/2015, Vol. 112 Issue 11, p1835 

    A letter to the editor is presented in response to the article "Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy," by K. S. Courneya and colleagues in the 2014 issue.

  • Application of a Drug-Induced Apoptosis Assay to Identify Treatment Strategies in Recurrent or Metastatic Breast Cancer. Bosserman, Linda; Rogers, Karl; Willis, Carl; Davidson, Dirk; Whitworth, Pat; Karimi, Misagh; Upadhyaya, Gargi; Rutledge, James; Hallquist, Allan; Perree, Mathieu; Presant, Cary A. // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: A drug-induced apoptosis assay has been developed to determine which chemotherapy drugs or regimens can produce higher cell killing in vitro. This study was done to determine if this assay could be performed in patients with recurrent or metastatic breast cancer patients, to...

  • Mammographic Findings after Intraoperative Radiotherapy of the Breast. Rivera, Ronald; Smith-Bronstein, Virginia; Villegas-Mendez, Sylvia; Rayhanabad, Jessica; Sheth, Pulin; Rashtianq, Afshin; Holmes, Dennis R. // Radiology Research & Practice;2012, p1 

    Intraoperative Radiotherapy (IORT) is a form of accelerated partial breast radiation that has been shown to be equivalent to conventional whole breast external beam radiotherapy (EBRT) in terms of local cancer control. However, questions have been raised about the potential of f IORT to produce...

  • ATTOM AND ATLAS COMBINED DATA. Lohrisch, Caroline // Oncology Exchange;Aug2013, Vol. 12 Issue 3, p30 

    The author discusses a randomized trial for the longer use of tamoxifen to 10 years in treating patients with breast cancer. The results of this study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois from May 31 to June 4, 2013....

  • Selective use of whole breast radiotherapy after breast conserving surgery for invasive breast cancer and DCIS. Skandarajah, Anita R.; Bruce Mann, G. // Surgeon (Elsevier Science);Oct2013, Vol. 11 Issue 5, p278 

    Background: Radiotherapy following breast conservation is routine in the treatment of invasive breast cancer and is commonly used in ductal carcinoma in situ to decrease local recurrence. However, adjuvant breast radiotherapy has significant short and longer-term side effects and consumes...

  • Randomised trial will evaluate tibolone in breast cancer patients. Bundred, Nigel // Journal of the British Menopause Society;2003, Vol. 9 Issue 3, p99 

    The article reports on a study investigating the effects of tibolone treatment on breast cancer recurrence and menopausal symptoms in women being treated for breast cancer. The study, which is expected to be completed by 2008, aims to conduct randomized trials on a worldwide total of 2600...

  • Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. Dieli-Conwright, Christina M.; Mortimer, Joanne E.; Schroeder, E. Todd; Courneya, Kerry; Demark-Wahnefried, Wendy; Buchanan, Thomas A.; Tripathy, Debu; Bernstein, Leslie // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background: Metabolic syndrome (MetS) is increasingly present in breast cancer survivors, possibly worsened by cancer-related treatments, such as chemotherapy. MetS greatly increases risk of cardiovascular disease and diabetes, co-morbidities that could impair the survivorship experience, and...

  • Decrease social inequalities return-to-work: development and design of a randomised controlled trial among women with breast cancer. Vidor, Clémence; Leroyer, Ariane; Christophe, Véronique; Seillier, Mélanie; Foncel, Jérome; Van de Maële, Justine; Bonneterre, Jacques; Fantoni, Sophie // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Despite the improvement in the care management, women cancer patients who are still in employment find themselves for the most part obliged to stop working while they are having treatment. Their return-to-work probability is impacted by numerous psychosocial factors. The objective is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics